// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

The efficacy of lateral wedge insoles for painful medial knee osteoarthritis after patient screening: a randomised trial

D.T. Felson - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Inflammatory Arthritis

N/A

Six months’ treatment with MIV-711, a novel Cathepsin K inhibitor induces osteoarthritis structure modification: results from a randomized double-blind placebo-controlled phase IIA trial

P.G. Conaghan - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

MIV711

Inhibition of LRP1 shedding reverses cartilage degradation in osteoarthritis

K. Yamamoto - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

A genetic risk score approach to assess the relationship between lipids and osteoarthritis

M.S. Yau - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

lipase

Hip arthroscopy compared to best conservative care for the treatment of femoroacetabular impingement syndrome: a randomised controlled trial (UK FASHIoN)

D.R. Griffin - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Identification and characterisation of long non-coding RNAS expressed and dysregulated in knee and hip osteoarthritic cartilage

M.J. Barter - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Stratification of knee osteoarthritis: two major patient subgroups identified by genome wide expression analysis of articular cartilage

J. Soul - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

N/A

Causal effects for higher body mass index, but not for triglyceride levels or genetic predisposition to type 2 diabetes, on osteoarthritis

F.P. Hartwig - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Type 2 diabetes mellitus

N/A

In vivo pulsed SILAC labeling reveals distinctive, age-dependent, turnover rates of collagens of articular cartilage and bone

Y. Ariosa-Morejon - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

KIF26B is necessary for osteogenic transdifferentiation and mineralisation in an in vitro model of heterotopic ossification

G. Pickering - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Fibroblast growth factor 2 promotes regeneration of cartilage by attracting mesenchymal stem cells to the site of cartilage injury

S.N. Khan - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

sodium pyruvate

The natural history of flare-ups: a daily diary study of patients with, or at high risk of, knee osteoarthritis

E. Parry - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

N/A

Lymphoid enhancer binding factor 1-mediated Matrix metalloproteinase 13 gene expression is repressed by SIRT1 in human chondrocytes

J. Elayyan - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Lipidomic profiling of human synovial fluid: metabolites generated by the soluble epoxide hydrolase are associated with increased risk of knee osteoarthritis and radiographic progression

A.M. Valdes - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

N/A

Defining the phenotype of the human fetal notochordal cell: implications for intervertebral disc regeneration

L. Ward - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Implementing international osteoarthritis guidelines in an integrated care model – results from a cluster randomized controlled trial

N. sters - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Identification of tissue-specific biomarkers in knee osteoarthritis synovial fluid: a proteomic approach

U. Timur - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

N/A

A role for the snoRNA U3 in the altered translational capacity of ageing and osteoarthritic chondrocytes

M.J. Peffers - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Interleukin

Patient-reported outcome 32 to 37 years following surgically treated or non-surgically treated acute anterior cruciate ligament injury

S.R. Filbay - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Hypomorphic conditional deletion of E11/podoplanin in the subchondral bone protects against load-induced osteoarthritis

K.A. Staines - Osteoarthritis Research Society International (OARSI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

Isoflurane

Copyright © 2026. QuantiNova All rights reserved